A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome
Identifieur interne : 000A48 ( Istex/Corpus ); précédent : 000A47; suivant : 000A49A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome
Auteurs : Ludger Grote ; Lena Leissner ; Jan Hedner ; Jan UlfbergSource :
- Movement Disorders [ 0885-3185 ] ; 2009-07-30.
English descriptors
Abstract
Iron deficiency may exacerbate symptoms in the Restless Legs Syndrome (RLS). We investigated the effect of intravenous iron sucrose or placebo on symptoms in patients with RLS and mild to moderate iron deficit. Sixty patients with primary RLS (seven males, age 46 (9) years, S‐ferritin ≤45 μg/L) recruited from a cohort of 231 patients were randomly assigned in a 12‐months double‐blind, multi‐centre study of iron sucrose 1000 mg (n = 29) or saline (n = 31). The primary efficacy variable was the RLS severity scale (IRLS) score at week 11. Median IRLS score decreased from 24 to 7 (week 11) after iron sucrose and from 26 to 17 after placebo (P = 0.123, N.S. for between treatment comparison). The corresponding scores at week 7 were 12 and 20 in the two groups (P = 0.017). Drop out rate because of lack of efficacy at 12 months was 19/31 after placebo and 5/29 patients after iron sucrose (Kaplan–Meier estimate, log rank test P = 0.0006) suggesting an iron induced superior long term RLS symptom control. Iron sucrose was well tolerated. This study showed a lack of superiority of iron sucrose at 11 weeks but found evidence that iron sucrose reduced RLS symptoms both in the acute phase (7 weeks) and during long‐term follow up in patients with variable degree of iron deficiency. Further studies on target patient groups, dosing and dosing intervals are warranted before iron sucrose could be considered for treatment of iron deficient patients with RLS. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22562
Links to Exploration step
ISTEX:89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome</title><author><name sortKey="Grote, Ludger" sort="Grote, Ludger" uniqKey="Grote L" first="Ludger" last="Grote">Ludger Grote</name><affiliation><mods:affiliation>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Leissner, Lena" sort="Leissner, Lena" uniqKey="Leissner L" first="Lena" last="Leissner">Lena Leissner</name><affiliation><mods:affiliation>Sleep Unit, Department of Neurology, Örebro University Hospital, Örebro, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Hedner, Jan" sort="Hedner, Jan" uniqKey="Hedner J" first="Jan" last="Hedner">Jan Hedner</name><affiliation><mods:affiliation>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Ulfberg, Jan" sort="Ulfberg, Jan" uniqKey="Ulfberg J" first="Jan" last="Ulfberg">Jan Ulfberg</name><affiliation><mods:affiliation>Sleep Disorder Center, Avesta Hospital, Avesta, Sweden</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22562</idno><idno type="url">https://api.istex.fr/document/89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome</title><author><name sortKey="Grote, Ludger" sort="Grote, Ludger" uniqKey="Grote L" first="Ludger" last="Grote">Ludger Grote</name><affiliation><mods:affiliation>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Leissner, Lena" sort="Leissner, Lena" uniqKey="Leissner L" first="Lena" last="Leissner">Lena Leissner</name><affiliation><mods:affiliation>Sleep Unit, Department of Neurology, Örebro University Hospital, Örebro, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Hedner, Jan" sort="Hedner, Jan" uniqKey="Hedner J" first="Jan" last="Hedner">Jan Hedner</name><affiliation><mods:affiliation>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Ulfberg, Jan" sort="Ulfberg, Jan" uniqKey="Ulfberg J" first="Jan" last="Ulfberg">Jan Ulfberg</name><affiliation><mods:affiliation>Sleep Disorder Center, Avesta Hospital, Avesta, Sweden</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-07-30">2009-07-30</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1445">1445</biblScope><biblScope unit="page" to="1452">1452</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5</idno><idno type="DOI">10.1002/mds.22562</idno><idno type="ArticleID">MDS22562</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>clinical trial</term><term>iron deficiency</term><term>iron sucrose</term><term>restless legs syndrome</term><term>treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Iron deficiency may exacerbate symptoms in the Restless Legs Syndrome (RLS). We investigated the effect of intravenous iron sucrose or placebo on symptoms in patients with RLS and mild to moderate iron deficit. Sixty patients with primary RLS (seven males, age 46 (9) years, S‐ferritin ≤45 μg/L) recruited from a cohort of 231 patients were randomly assigned in a 12‐months double‐blind, multi‐centre study of iron sucrose 1000 mg (n = 29) or saline (n = 31). The primary efficacy variable was the RLS severity scale (IRLS) score at week 11. Median IRLS score decreased from 24 to 7 (week 11) after iron sucrose and from 26 to 17 after placebo (P = 0.123, N.S. for between treatment comparison). The corresponding scores at week 7 were 12 and 20 in the two groups (P = 0.017). Drop out rate because of lack of efficacy at 12 months was 19/31 after placebo and 5/29 patients after iron sucrose (Kaplan–Meier estimate, log rank test P = 0.0006) suggesting an iron induced superior long term RLS symptom control. Iron sucrose was well tolerated. This study showed a lack of superiority of iron sucrose at 11 weeks but found evidence that iron sucrose reduced RLS symptoms both in the acute phase (7 weeks) and during long‐term follow up in patients with variable degree of iron deficiency. Further studies on target patient groups, dosing and dosing intervals are warranted before iron sucrose could be considered for treatment of iron deficient patients with RLS. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Ludger Grote MD, PhD</name><affiliations><json:string>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</json:string></affiliations></json:item><json:item><name>Lena Leissner MD</name><affiliations><json:string>Sleep Unit, Department of Neurology, Örebro University Hospital, Örebro, Sweden</json:string></affiliations></json:item><json:item><name>Jan Hedner MD, PhD</name><affiliations><json:string>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</json:string></affiliations></json:item><json:item><name>Jan Ulfberg MD, PhD</name><affiliations><json:string>Sleep Disorder Center, Avesta Hospital, Avesta, Sweden</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>iron sucrose</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>restless legs syndrome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>iron deficiency</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinical trial</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Iron deficiency may exacerbate symptoms in the Restless Legs Syndrome (RLS). We investigated the effect of intravenous iron sucrose or placebo on symptoms in patients with RLS and mild to moderate iron deficit. Sixty patients with primary RLS (seven males, age 46 (9) years, S‐ferritin ≤45 μg/L) recruited from a cohort of 231 patients were randomly assigned in a 12‐months double‐blind, multi‐centre study of iron sucrose 1000 mg (n = 29) or saline (n = 31). The primary efficacy variable was the RLS severity scale (IRLS) score at week 11. Median IRLS score decreased from 24 to 7 (week 11) after iron sucrose and from 26 to 17 after placebo (P = 0.123, N.S. for between treatment comparison). The corresponding scores at week 7 were 12 and 20 in the two groups (P = 0.017). Drop out rate because of lack of efficacy at 12 months was 19/31 after placebo and 5/29 patients after iron sucrose (Kaplan–Meier estimate, log rank test P = 0.0006) suggesting an iron induced superior long term RLS symptom control. Iron sucrose was well tolerated. This study showed a lack of superiority of iron sucrose at 11 weeks but found evidence that iron sucrose reduced RLS symptoms both in the acute phase (7 weeks) and during long‐term follow up in patients with variable degree of iron deficiency. Further studies on target patient groups, dosing and dosing intervals are warranted before iron sucrose could be considered for treatment of iron deficient patients with RLS. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>7.033</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1494</abstractCharCount><pdfWordCount>4033</pdfWordCount><pdfCharCount>25337</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>252</abstractWordCount></qualityIndicators><title>A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome</title><genre><json:string>Serial article</json:string></genre><host><volume>24</volume><pages><total>8</total><last>1452</last><first>1445</first></pages><issn><json:string>0885-3185</json:string></issn><issue>10</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22562</json:string></doi><id>89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note><note>Renapharma Ltd, Uppsala, Sweden</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome</title><author><persName><forename type="first">Ludger</forename><surname>Grote</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, SE‐ 413 45 Gothenburg, Sweden</p></note><affiliation>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation></author><author><persName><forename type="first">Lena</forename><surname>Leissner</surname><roleName type="degree">MD</roleName></persName><affiliation>Sleep Unit, Department of Neurology, Örebro University Hospital, Örebro, Sweden</affiliation></author><author><persName><forename type="first">Jan</forename><surname>Hedner</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation></author><author><persName><forename type="first">Jan</forename><surname>Ulfberg</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Sleep Disorder Center, Avesta Hospital, Avesta, Sweden</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-07-30"></date><biblScope unit="vol">24</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1445">1445</biblScope><biblScope unit="page" to="1452">1452</biblScope></imprint></monogr><idno type="istex">89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5</idno><idno type="DOI">10.1002/mds.22562</idno><idno type="ArticleID">MDS22562</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Iron deficiency may exacerbate symptoms in the Restless Legs Syndrome (RLS). We investigated the effect of intravenous iron sucrose or placebo on symptoms in patients with RLS and mild to moderate iron deficit. Sixty patients with primary RLS (seven males, age 46 (9) years, S‐ferritin ≤45 μg/L) recruited from a cohort of 231 patients were randomly assigned in a 12‐months double‐blind, multi‐centre study of iron sucrose 1000 mg (n = 29) or saline (n = 31). The primary efficacy variable was the RLS severity scale (IRLS) score at week 11. Median IRLS score decreased from 24 to 7 (week 11) after iron sucrose and from 26 to 17 after placebo (P = 0.123, N.S. for between treatment comparison). The corresponding scores at week 7 were 12 and 20 in the two groups (P = 0.017). Drop out rate because of lack of efficacy at 12 months was 19/31 after placebo and 5/29 patients after iron sucrose (Kaplan–Meier estimate, log rank test P = 0.0006) suggesting an iron induced superior long term RLS symptom control. Iron sucrose was well tolerated. This study showed a lack of superiority of iron sucrose at 11 weeks but found evidence that iron sucrose reduced RLS symptoms both in the acute phase (7 weeks) and during long‐term follow up in patients with variable degree of iron deficiency. Further studies on target patient groups, dosing and dosing intervals are warranted before iron sucrose could be considered for treatment of iron deficient patients with RLS. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>iron sucrose</term></item><item><term>restless legs syndrome</term></item><item><term>treatment</term></item><item><term>iron deficiency</term></item><item><term>clinical trial</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-07-07">Received</change><change when="2009-02-26">Registration</change><change when="2009-07-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="100"><doi origin="wiley" registered="yes">10.1002/mds.v24:10</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">10</numbering></numberingGroup><coverDate startDate="2009-07-30">30 July 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="40" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22562</doi><idGroup><id type="unit" value="MDS22562"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-07-07"></event><event type="manuscriptRevised" date="2009-02-11"></event><event type="manuscriptAccepted" date="2009-02-26"></event><event type="publishedOnlineEarlyUnpaginated" date="2009-06-01"></event><event type="firstOnline" date="2009-06-01"></event><event type="publishedOnlineFinalForm" date="2009-07-24"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1445</numbering><numbering type="pageLast">1452</numbering></numberingGroup><correspondenceTo>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, SE‐ 413 45 Gothenburg, Sweden</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22562.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="4"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="28"></count><count type="wordTotal" number="4818"></count></countGroup><titleGroup><title type="main" xml:lang="en">A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome<link href="#fn1"></link></title><title type="short" xml:lang="en">Treatment of Restless Legs Syndrome</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Ludger</givenNames><familyName>Grote</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>ludger.grote@lungall.gu.se</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Lena</givenNames><familyName>Leissner</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jan</givenNames><familyName>Hedner</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Jan</givenNames><familyName>Ulfberg</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="SE" type="organization"><unparsedAffiliation>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="SE" type="organization"><unparsedAffiliation>Sleep Unit, Department of Neurology, Örebro University Hospital, Örebro, Sweden</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="SE" type="organization"><unparsedAffiliation>Sleep Disorder Center, Avesta Hospital, Avesta, Sweden</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">iron sucrose</keyword><keyword xml:id="kwd2">restless legs syndrome</keyword><keyword xml:id="kwd3">treatment</keyword><keyword xml:id="kwd4">iron deficiency</keyword><keyword xml:id="kwd5">clinical trial</keyword></keywordGroup><fundingInfo><fundingAgency>Renapharma Ltd, Uppsala, Sweden</fundingAgency></fundingInfo><supportingInformation><p> Additional Supporting Information may be found in the online version of this article. </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22562:MDS_22562_sm_SuppInfo"></mediaResource><caption>Supporting Information</caption></supportingInfoItem><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22562:MDS_22562_sm_SuppFig-1"></mediaResource><caption>Supporting Figure 1: Short‐, intermediate‐, and long‐term effects of iron sucrose and placebo on RLS symptoms. Shown as the median values of the IRLS score at baseline (week 0) and at follow up weeks 3, 7, 11, and months 5, 8, and 12. (ITT analysis, n=29 for the iron sucrose group and n=31 for the placebo group)</caption></supportingInfoItem><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22562:MDS_22562_sm_SuppTable-1"></mediaResource><caption>Supporting Table 1: Adverse reactions during the study. Number of adverse reactions and percentage of all reported reactions listed in certain categories. Different events may have occurred in one individual patient and at repeated occasions.</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Iron deficiency may exacerbate symptoms in the Restless Legs Syndrome (RLS). We investigated the effect of intravenous iron sucrose or placebo on symptoms in patients with RLS and mild to moderate iron deficit. Sixty patients with primary RLS (seven males, age 46 (9) years, S‐ferritin ≤45 μg/L) recruited from a cohort of 231 patients were randomly assigned in a 12‐months double‐blind, multi‐centre study of iron sucrose 1000 mg (n = 29) or saline (n = 31). The primary efficacy variable was the RLS severity scale (IRLS) score at week 11. Median IRLS score decreased from 24 to 7 (week 11) after iron sucrose and from 26 to 17 after placebo (<i>P</i> = 0.123, N.S. for between treatment comparison). The corresponding scores at week 7 were 12 and 20 in the two groups (<i>P</i> = 0.017). Drop out rate because of lack of efficacy at 12 months was 19/31 after placebo and 5/29 patients after iron sucrose (Kaplan–Meier estimate, log rank test <i>P</i> = 0.0006) suggesting an iron induced superior long term RLS symptom control. Iron sucrose was well tolerated. This study showed a lack of superiority of iron sucrose at 11 weeks but found evidence that iron sucrose reduced RLS symptoms both in the acute phase (7 weeks) and during long‐term follow up in patients with variable degree of iron deficiency. Further studies on target patient groups, dosing and dosing intervals are warranted before iron sucrose could be considered for treatment of iron deficient patients with RLS. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Treatment of Restless Legs Syndrome</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome</title></titleInfo><name type="personal"><namePart type="given">Ludger</namePart><namePart type="family">Grote</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation><description>Correspondence: Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, SE‐ 413 45 Gothenburg, Sweden</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lena</namePart><namePart type="family">Leissner</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Sleep Unit, Department of Neurology, Örebro University Hospital, Örebro, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jan</namePart><namePart type="family">Hedner</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jan</namePart><namePart type="family">Ulfberg</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Sleep Disorder Center, Avesta Hospital, Avesta, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-07-30</dateIssued><dateCaptured encoding="w3cdtf">2008-07-07</dateCaptured><dateValid encoding="w3cdtf">2009-02-26</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">4</extent><extent unit="tables">2</extent><extent unit="references">28</extent><extent unit="words">4818</extent></physicalDescription><abstract lang="en">Iron deficiency may exacerbate symptoms in the Restless Legs Syndrome (RLS). We investigated the effect of intravenous iron sucrose or placebo on symptoms in patients with RLS and mild to moderate iron deficit. Sixty patients with primary RLS (seven males, age 46 (9) years, S‐ferritin ≤45 μg/L) recruited from a cohort of 231 patients were randomly assigned in a 12‐months double‐blind, multi‐centre study of iron sucrose 1000 mg (n = 29) or saline (n = 31). The primary efficacy variable was the RLS severity scale (IRLS) score at week 11. Median IRLS score decreased from 24 to 7 (week 11) after iron sucrose and from 26 to 17 after placebo (P = 0.123, N.S. for between treatment comparison). The corresponding scores at week 7 were 12 and 20 in the two groups (P = 0.017). Drop out rate because of lack of efficacy at 12 months was 19/31 after placebo and 5/29 patients after iron sucrose (Kaplan–Meier estimate, log rank test P = 0.0006) suggesting an iron induced superior long term RLS symptom control. Iron sucrose was well tolerated. This study showed a lack of superiority of iron sucrose at 11 weeks but found evidence that iron sucrose reduced RLS symptoms both in the acute phase (7 weeks) and during long‐term follow up in patients with variable degree of iron deficiency. Further studies on target patient groups, dosing and dosing intervals are warranted before iron sucrose could be considered for treatment of iron deficient patients with RLS. © 2009 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><note type="funding">Renapharma Ltd, Uppsala, Sweden</note><subject lang="en"><genre>Keywords</genre><topic>iron sucrose</topic><topic>restless legs syndrome</topic><topic>treatment</topic><topic>iron deficiency</topic><topic>clinical trial</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supporting Information - Supporting Figure 1: Short‐, intermediate‐, and long‐term effects of iron sucrose and placebo on RLS symptoms. Shown as the median values of the IRLS score at baseline (week 0) and at follow up weeks 3, 7, 11, and months 5, 8, and 12. (ITT analysis, n=29 for the iron sucrose group and n=31 for the placebo group) - Supporting Table 1: Adverse reactions during the study. Number of adverse reactions and percentage of all reported reactions listed in certain categories. Different events may have occurred in one individual patient and at repeated occasions. - </note><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1445</start><end>1452</end><total>8</total></extent></part></relatedItem><identifier type="istex">89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5</identifier><identifier type="DOI">10.1002/mds.22562</identifier><identifier type="ArticleID">MDS22562</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:89BCBB5535CC93038CC43B6AEA9EC23D367BB2C5
|texte= A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |